Management of albuminuria. Moment of nephrology referral
DOI:
https://doi.org/10.47196/diab.v51i3.105Keywords:
albuminuria, glycemia monitoring, blood pressure controlAbstract
In the last years new observations arise that allowed to unders- tand that the clinical course of kidney disease caused by diabetes might be different from the traditional description. One of the first current concepts is the recommendation of replacing the term micro and macroalbuminuria by albuminuria, which is classified according to its severity in stages A1, A2 and A3. The detection of albuminuria as single marker of kidney disease does not seem to be sufficient for the early diagnosis, it is also necessary the monitoring of the renal function using estimating equations of the glomerular filtration (GF). The strict monitoring of glycemia, blood pressure (BP) and the use of IECA or ARA II continue being the fundamental treatment of albuminuria. For glycemia monitoring, it may be convenient to consider the additional benefits of anti- diabetic drugs. Nephrology referral should be considered according to the stage of albuminuria and GF deterioration.
References
Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal in- sufficiency in the absence of albuminuria and reti- nopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289(24):3273-7.
KDIGO 2012. Clinical practice guideline for the evalua- tion and management of chronic kidney disease. Kid- ney Int. 2013; (3):1-163.
Molitch ME, Steffes M, Sun W, et al. Development and progression of renal insufficiency with and without al- buminuria in adults with type 1 diabetes in the diabe- tes control and complications trial and the epidemiolo- gy of diabetes interventions and complications study. Diabetes Care 2010; 33(7):1536-43.
Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55:1832-1839.
Kim SS, Kim JH, Kim IJ. Current challenges in diabe- tic nephropathy: early diagnosis and ways to improve outcomes. Endocrinol Metab 2016; 31(2):245-53.
Halimi JM. The emerging concept of chronic kidney di- sease without clinical proteinuria in diabetic patients. Diabetes Metab 2012; 38(4):291-7.
Roscioni SS, Lambers Heerspink HJ, de Zeeuw D. Mi- croalbuminuria: target for renoprotective therapy PRO. Kidney Int 2014; 86(1):40-9.
Stephen R, Jolly SE, Nally JV Jr, et al. Albuminuria: when urine predicts kidney and cardiovascular disea- se. Cleve Clin J Med 2014; 81(1):41-50.
Kitada M, Kanasaki K, Koya D. Clinical therapeutic stra- tegies for early stage of diabetic kidney disease. World J Diabetes 2014; 5(3):342-56.
Russo LM, Sandoval RM, Campos SB, et al. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009; 20(3):489-94.
Tojo A, Kinugasa S. Mechanisms of glomerular albu- min filtration and tubular reabsorption. International Journal of Nephrology 2012; 1-9.
Dickson LE, Wagner MC, Sandoval RM, Molitoris BA. The proximal tubule and albuminuria: really. J Am Soc Nephrol 2014; 25(3):443-53.
Kowalski A, Krikorian A, Lerma EV. Diabetic nephro- pathy for the primary care provider: new understan- dings on early detection and treatment. Ochsner J 2014; 14(3):369-79.
Fried LF, Emanuele N, Zhang JH, et al; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369(20):1892-903.
Quiroga B, Arroyo D, de Arriba G. Present and future in the treatment of diabetic kidney disease. J Diabetes Res 2015; 1-13.
MavrakanasTA, Gariani K, Martin PY. Mineralocorticoid receptor blockade in addition to angiotensin conver- ting enzyme inhibitor or angiotensin II receptor bloc- ker treatment: an emerging paradigm in diabetic ne- phropathy: a systematic review. Eur J Intern Med 2014; 25(2):173-6.
Agarwal R. Vitamin D, proteinuria, diabetic nephro- pathy, and progression of CKD. Clin J Am Soc Nephrol 2009; 4(9):1523-8.
Vallon V, et al. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT-2 inhibition. Diabetologia 2016; 60 (2):215-225.
Fioretto P, Zambon A, Rossato M, et al. SGLT-2 inhi- bitors and the diabetic kidney. Diabetes Care 2016; 39(2):165-71.
Górriz JL, Nieto J, Navarro-González JF, et al. Nephro- protection by hypoglycemic agents: do we have sup- porting data? J Clin Med 2015; 4(10):1866-89.
Skov J. Effects of GLP-1 in the kidney. Rev Endocr Me- tab Disord 2014; 15(3):197-207.
Von Websky K, Reichetzeder C, Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens 2014; 23(1):54-60.
Haluzík M, Frolík J, Rychlík I. Renal effects of DPP-4 in- hibitors: a focus on microalbuminuria. International Journal of Endocrinology 2013; 7. Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabe- tic nephropathy and cardiovascular disease. Clin Sci. 2013; 124(1):17-26.
Caramori ML, Fioretto P, Mauer M. Enhancing the pre- dictive value of urinary albumin for diabetic nephro- pathy. J Am Soc Nephrol 2006; 17(2):339-52.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
